My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 250

    1.

    Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome.

    Esposito K, Ciotola M, Carleo D, Schisano B, Saccomanno F, Sasso FC, Cozzolino D, Assaloni R, Merante D, Ceriello A, Giugliano D.

    Diabetes Care. 2006 May;29(5):1071-6.PMID: 16644639 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.

    Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, Salvadeo SA, Pricolo F, Ferrari I, Gravina A, Ragonesi PD.

    Clin Ther. 2006 May;28(5):679-88. Erratum in: Clin Ther. 2006 Sep;28(9):1483. PMID: 16861090 [PubMed - indexed for MEDLINE]Related articles

    3.

    Relation of improvement in endothelium-dependent flow-mediated vasodilation after rosiglitazone to changes in asymmetric dimethylarginine, endothelin-1, and C-reactive protein in nondiabetic patients with the metabolic syndrome.

    Wang TD, Chen WJ, Cheng WC, Lin JW, Chen MF, Lee YT.

    Am J Cardiol. 2006 Oct 15;98(8):1057-62. Epub 2006 Aug 28.PMID: 17027571 [PubMed - indexed for MEDLINE]Related articles

    4.

    Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial.

    Esposito K, Marfella R, Ciotola M, Di Palo C, Giugliano F, Giugliano G, D'Armiento M, D'Andrea F, Giugliano D.

    JAMA. 2004 Sep 22;292(12):1440-6.PMID: 15383514 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    [Effects of rosiglitazone on endothelial function in non-diabetic subjects with metabolic syndrome]

    Bahia L, Aguiar LG, Villela N, Bottino D, Godoy-Matos AF, Bouskela E.

    Arq Bras Cardiol. 2006 May;86(5):366-73. Epub 2006 May 29. Portuguese. PMID: 16751941 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus.

    Kelly AS, Thelen AM, Kaiser DR, Gonzalez-Campoy JM, Bank AJ.

    Vasc Med. 2007 Nov;12(4):311-8.PMID: 18048467 [PubMed - indexed for MEDLINE]Related articles

    7.

    Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

    Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF.

    J Clin Pharm Ther. 2006 Aug;31(4):375-83.PMID: 16882108 [PubMed - indexed for MEDLINE]Related articles

    8.

    Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome.

    Wang TD, Chen WJ, Lin JW, Chen MF, Lee YT.

    Am J Cardiol. 2004 Feb 1;93(3):362-5.PMID: 14759393 [PubMed - indexed for MEDLINE]Related articles

    9.

    Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone.

    Derosa G, Fogari E, D'Angelo A, Cicero AF, Salvadeo SA, Ragonesi PD, Ferrari I, Gravina A, Fassi R, Fogari R.

    J Clin Pharm Ther. 2007 Jun;32(3):261-8.PMID: 17489878 [PubMed - indexed for MEDLINE]Related articles

    10.

    Adiponectin is associated with improvement of endothelial function after rosiglitazone treatment in non-diabetic individuals with metabolic syndrome.

    Bahia L, Aguiar LG, Villela N, Bottino D, Godoy-Matos AF, Geloneze B, Tambascia M, Bouskela E.

    Atherosclerosis. 2007 Nov;195(1):138-46. Epub 2006 Nov 3.PMID: 17084402 [PubMed - indexed for MEDLINE]Related articles

    11.

    Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride.

    Pfützner A, Schöndorf T, Seidel D, Winkler K, Matthaei S, Hamann A, Forst T.

    Metabolism. 2006 Jan;55(1):20-5.PMID: 16324915 [PubMed - indexed for MEDLINE]Related articles

    12.

    Effect of rosiglitazone on insulin resistance, C-reactive protein and endothelial function in non-obese young women with polycystic ovary syndrome.

    Tarkun I, Cetinarslan B, Türemen E, Sahin T, Cantürk Z, Komsuoglu B.

    Eur J Endocrinol. 2005 Jul;153(1):115-21.PMID: 15994753 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome.

    Derosa G, Cicero AF, Gaddi A, Ragonesi PD, Piccinni MN, Fogari E, Salvadeo S, Ciccarelli L, Fogari R.

    Diabetes Res Clin Pract. 2005 Jul;69(1):5-13. Epub 2004 Dec 29.PMID: 15955382 [PubMed - indexed for MEDLINE]Related articles

    14.

    Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial.

    Hadigan C, Yawetz S, Thomas A, Havers F, Sax PE, Grinspoon S.

    Ann Intern Med. 2004 May 18;140(10):786-94.PMID: 15148065 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome.

    Samaha FF, Szapary PO, Iqbal N, Williams MM, Bloedon LT, Kochar A, Wolfe ML, Rader DJ.

    Arterioscler Thromb Vasc Biol. 2006 Mar;26(3):624-30. Epub 2005 Dec 15.PMID: 16357312 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophy.

    Kovacic JC, Martin A, Carey D, Wand H, Mallon PW, Feneley MP, Emery S, Cooper DA, Carr A; ROSEY Investigators.

    Antivir Ther. 2005;10(1):135-43.PMID: 15751771 [PubMed - indexed for MEDLINE]Related articles

    17.

    Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia.

    Koh KK, Han SH, Quon MJ, Yeal Ahn J, Shin EK.

    Diabetes Care. 2005 Jun;28(6):1419-24.PMID: 15920062 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and tolerability of combination therapy with rosiglitazone and sulfonylurea in African American and Hispanic American patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy.

    Davidson JA, McMorn SO, Waterhouse BR, Cobitz AR.

    Clin Ther. 2007 Sep;29(9):1900-14.PMID: 18035190 [PubMed - indexed for MEDLINE]Related articles

    19.

    Rosiglitazone improves insulin sensitivity in nonobese subjects with impaired glucose tolerance: the role of adiponectin and C-reactive protein.

    Hung YJ, Lin SH, Pei D, Kuo SW, Hsieh CH, He CT, Hsing Lee C, Fan SC, Sheu WH.

    Metabolism. 2006 Apr;55(4):439-44.PMID: 16546473 [PubMed - indexed for MEDLINE]Related articles

    20.

    Effects of simvastatin and metformin on inflammation and insulin resistance in individuals with mild metabolic syndrome.

    Bulcão C, Ribeiro-Filho FF, Sañudo A, Roberta Ferreira SG.

    Am J Cardiovasc Drugs. 2007;7(3):219-24.PMID: 17610348 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity